The West Clinic

Germantown, Tennessee 38138

3 studies enrolling now · 26 studies all time

What they study most

Adenocarcinoma of the Pancreas, Advanced Cancer, Biliary Tract Cancer, Breast Cancer, Carcinoma, Carcinoma, Non-small Cell Lung, Chronic Lymphocytic Leukemia, Clear Cell Renal Cell Carcinoma, Early Breast Cancer, Early-Stage Breast Carcinoma, Endometrial Adenocarcinoma, Endometrial Carcinoma

Studies at this site

• A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02) — Recruiting now
• A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer — Recruiting now
• Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC — Recruiting now
• Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study — Running, not enrolling
• Avelumab Program Rollover Study — Running, not enrolling
• Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2) — Running, not enrolling
• A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer — Running, not enrolling
• A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy — Running, not enrolling
• DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02] — Completed
• A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma — Completed
• Olaratumab (LY3012207) Patient Access for Soft Tissue Sarcoma — APPROVED_FOR_MARKETING
• A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib — Completed
• A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001) — Running, not enrolling
• Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations — Stopped early
• Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer — Completed
• Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects — Status unconfirmed
• Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer — Stopped early
• PEN-866 in Patients With Advanced Solid Malignancies — Status unconfirmed
• Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor) — Completed
• Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer — Completed
• Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies — Completed
• A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC) — Completed
• A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer — Completed
• POA Prospective Repository — Status unconfirmed
• Concordance of Inivata Liquid Biopsy With Standard of Care Tissue Testing — Completed
• Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer — Completed